In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skyepharma:Trying To Take Off From a Short Runway

Executive Summary

Since 1998, through a series of inexpensive acquisitions, SkyePharma has assembled a wide range of drug delivery technologies, positioning itself as a one stop shop. But the company still has to convince both its customers, and its investors, that it has not sacrificed quality for quantity.

You may also be interested in...



Delivering Profits at SkyePharma

SkyePharma fulfilled its profitability promise in 2002. Yet warnings of a revenue slip in the middle of 2003 have highlighted the group's reliance on the timing of uncertain milestones. But by building up its clinical and regulatory capabilities, increasing the proportion of its revenues derived from royalties, and leveraging a full pipeline which includes improved biologics, SkyePharma aims to increase its development control over its own and partners' programs and thereby maintain and grow its newfound profitability.

Some Big Year-End Dealmaking From SkyePharma

SkyePharma keeps its promise of profitability in 2002 by licensing its two most prominent pipeline candidates to Endo Pharmaceuticals. But now that the company has reached that benchmark, longer-term growth may require it to develop its own commercial capabilities.

Eurand: Oral Drug Delivery Solutions for Big Pharma Problems

Focused on small-molecule oral drug delivery and with a proven technology for solubilizing compounds, Eurand believes it can win the lion's share of a growing market for rescuing insoluble development-stage candidates, while at the same time increasing its percentage of the drugs' profits.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV001645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel